NDAORALTABLET
Approved
Apr 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
3/8 — Basic
MAVIK (trandolapril) by AbbVie is angiotensin-converting enzyme inhibitors [moa]. First approved in 1996.
Drug data last refreshed 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAVIK (trandolapril) is an oral ACE inhibitor tablet approved in 1996 for hypertension and heart failure. It works by inhibiting angiotensin-converting enzyme, reducing vasoconstriction and aldosterone secretion to lower blood pressure and improve cardiac function. The drug is indicated for patients with elevated blood pressure or reduced ejection fraction.
LOE Approaching
As a legacy ACE inhibitor facing loss of exclusivity, MAVIK teams are likely focused on cost management and retention rather than growth, signaling smaller commercial footprints.
Mechanism of Action
Angiotensin-converting Enzyme Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients
Started Dec 2008
7,993 enrolled
Hypertension
Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fed Conditions
Started Mar 2006
52 enrolled
Healthy
Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fasting Conditions
Started Mar 2006
52 enrolled
Healthy
Trandolapril 4 mg Tablet Under Non-Fasting Conditions
Started Oct 2004
50 enrolled
Healthy
Trandolapril 4 mg Tablet Under Fasting Conditions
Started Oct 2004
40 enrolled
Healthy
Worked on MAVIK at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.